The Mark Foundation for Cancer Research is dedicated to accelerating exciting academic discoveries into new therapies and platforms that will substantially improve outcomes for cancer patients. Currently, there are few options for academic scientists to obtain the resources and know-how to advance drug discovery efforts for promising new cancer targets.
To stem this gap, The Mark Foundation has established the Drug Discovery Award program. Through this program, The Mark Foundation aligns with investigators working to discover and progress a new therapeutic agent into preclinical development, providing not only resources to support post-target validation through early lead development but also the expertise of seasoned biopharma R&D scientists who will advise on activities on the critical path to developing a new therapeutic agent.
In March 2026, The Mark Foundation awarded four new Drug Discovery Awards. Learn more about their work:
